Wednesday, December 6, 2023
HomeSleep MedicineTraits that define device treatment of obstructive sleep apnoea

Traits that define device treatment of obstructive sleep apnoea

Certain traits may define a type of obstructive sleep apnoea (OSA) that can be effectively treated with an oral appliance, rather than continuous positive airway pressure (CPAP), according to research published in the Annals of the American Thoracic Society. With OSA there are times during sleep when air cannot flow normally into the lungs. The collapse of the soft tissues in the back of the throat or tongue usually causes the airflow obstruction.

Continuous positive airway pressure (CPAP), is considered the gold standard for preventing the obstruction by blowing air through a mask into the nose and throat. However, many patients have trouble sleeping with CPAP. For these patients, an oral appliance that moves the lower jaw forward to prevent the periods of obstructed airflow is often an alternative.

The study identifies five traits that appear to determine the effectiveness of an oral appliance in treating OSA.

"Sleep apnoea is not all the same, but we only recently developed ways to look at a sleep study and determine what traits cause the condition in different patients," said senior author Dr Scott Sands, assistant professor of medicine at Harvard Medical School and Brigham and Women's Hospital in Boston. "Since oral appliances work by improving the collapsibility of the upper airway, patients without really severe collapsibility are more likely to benefit from an oral appliance, while those with sleep apnoea caused by other traits, such as exaggerated reflex responses to drops in oxygen levels, are less likely to benefit."

The researchers used their new technology to measure the traits causing sleep apnoea through polysomnography, the test used to diagnose sleep apnoea. For this study, the researchers analysed polysomnographic data already gathered from 93 adults (average age: 56) who were diagnosed with moderate to severe OSA.

The authors looked at two traits related to the upper airway: collapsibility and muscle compensation. The researchers found that patients without severe collapsibility benefitted more from the oral appliance than those without this trait. Those with a weaker reflex response of the throat muscles that act to maintain an open airway (lower muscle compensation) also benefitted more than those with a stronger reflex response. Patients with very mild collapsibility, indicating deficits in other traits, responded less well.

The researchers also found that three traits unrelated to the upper airway helped predict those patients who would respond less well to an oral appliance: higher loop gain, lower arousal threshold and higher ventilatory response to arousal.

Loop gain is a measure of how aggressively the brain and lungs respond to falling oxygen and rising carbon dioxide in the blood. Arousal threshold is a measure of how easily a person wakes up from sleep; deeper sleep (higher arousal threshold) promotes better breathing.

Based on these five traits, oral appliances were predicted to be effective in treating sleep apnoea in more than half (61%) of the participants. Patients in this group experienced a 73% reduction in the Apnoea-Hypopnea Index, which is the number of breathing pauses per hour lasting 10 seconds or longer. (Apnoea means no airflow and hypopnoea means reduction in airflow). With an oral appliance, they had just eight apnoeas/hypopneas per hour.

The other patient group experienced a smaller reduction in the Apnoea-Hypopnea Index and had twice the number of breathing pauses remaining with the oral appliance.
The authors said that responses to oral appliances in their study could not be predicted by the severity of sleep apnoea or how overweight patients were. "Surprisingly, it didn't seem to matter whether sleep apnoea was moderate or very severe," Sands said. "Oral appliance therapy was remarkably effective in some quite overweight patients with very severe OSA."

Based on these findings, the authors write that, if their results are upheld in future studies, an oral appliance could be considered, along with CPAP, as a first-line therapy for treating a certain type of OSA.

"While CPAP is great for some, there remains a large group of patients who really struggle with it," Sands said. "For these folks, this study highlights the potential benefit of measuring the underlying causes of their sleep apnea to estimate whether an oral appliance might be an equivalent or better choice over CPAP for the treatment of their sleep apnoea."

Sands added that once the most useful measures for predicting patient outcomes are established, he believes they will be readily incorporated into routine sleep recording systems.

Rationale: Oral appliance therapy is efficacious in many patients with obstructive sleep apnea (OSA) but prediction of treatment outcome is challenging. Small, detailed physiological studies have identified key OSA endotypic traits (pharyngeal collapsibility and loop gain) as determinants of greater oral appliance efficacy.
Objectives: We used a clinically-applicable method to estimate OSA traits from routine polysomnography and identify an endotype-based subgroup of patients expected to show superior efficacy. Methods: In 93 patients (baseline apnea-hypopnea index [AHI] ≥20 events/hr), we examined whether polysomnography-estimated OSA traits (pharyngeal: collapsibility and muscle compensation; non-pharyngeal: loop gain, arousal threshold and ventilatory response to arousal) were associated with oral appliance efficacy (percent reduction in AHI from baseline) and could predict responses to treatment. Multivariable regression (with interactions) defined endotype-based subgroups of “predicted” responders and non-responders (based on 50% reduction in AHI). Treatment efficacy was compared between the predicted subgroups (with cross-validation).
Results: Greater oral appliance efficacy was associated with favorable non-pharyngeal traits (lower loop gain, higher arousal threshold and lower response to arousal), moderate (non-mild, non-severe) pharyngeal collapsibility and weaker muscle compensation (overall R2=0.30, adjusted R2=0.19, p=0.003). Predicted responders (N=54), compared with predicted non-responders (N=39), exhibited a greater reduction in AHI from baseline (73[66-79] vs. 51[38-61]%, mean[95%CI], p<0.0001) and a lower treatment AHI (8[6-11] vs. 16[12-20]events/hr, p=0.002). Differences persisted after adjusting for clinical covariates (including baseline AHI, body mass index, and neck circumference).
Conclusions: Quantifying OSA traits using clinical polysomnography can identify an endotype-based subgroup of patients that is highly responsive to oral appliance therapy. Prospective validation is warranted.

Ahmad A Bamagoos, Peter A Cistulli, Kate Sutherland, Melanie Madronio, Danny J. Eckert, Lauren Hess, Bradley A Edwards, Andrew Wellman, Scott A Sands

[link url=""]American Thoracic Society material[/link]
[link url=""]Annals of the American Thoracic Society abstract[/link]

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required